Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$11,191 Mln
P/E Ratio
17.76
P/B Ratio
3.01
Industry P/E
39.11
Debt to Equity
0.07
ROE
0.18 %
ROCE
--
Div. Yield
0.71 %
Book Value
--
EPS
64.35
CFO
₹332,484.00 Mln
EBITDA
₹487,123.00 Mln
Net Profit
₹243,887.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Dr. Reddy's Laboratories - ADR
| -13.62 | 7.57 | -8.02 | -4.76 | 6.78 | 6.09 | 1.44 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Dr. Reddy's Laboratories - ADR
| 13.35 | 34.45 | -20.88 | -8.25 | 75.68 | 7.64 | 0.37 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The... company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Address: 8-2-337, Road No. 3, Hyderabad, India, 500034 Read more
Co-Chairman, MD & Member of Management Council
Mr. Gunupati Venkateswara Prasad B.E.
Chairman of the Board & Member of the Management Council
Mr. Kallam Satish Reddy B.Tech., M.S.
Headquarters
Hyderabad
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Dr Reddy's Laboratories Ltd - ADR stood at $ 613,009 Mln as on 31-Dec-24
The share price of Dr Reddy's Laboratories Ltd - ADR is $13.64 (NYSE) as of 17-Apr-2025 13:33 EDT. Dr Reddy's Laboratories Ltd - ADR has given a return of 6.78% in the last 3 years.
Dr Reddy's Laboratories Ltd - ADR has a market capitalisation of $ 11,191 Mln as on 16-Apr-2025. As per Value Research classification, it is a company.
The P/B ratio of Dr Reddy's Laboratories Ltd - ADR is 3.01 times as on 16-Apr-2025, a 42% discount to its peers’ median range of 5.17 times.
The P/E ratio of Dr Reddy's Laboratories Ltd - ADR is 17.76 times as on 16-Apr-2025, a 55% discount to its peers’ median range of 39.11 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Dr Reddy's Laboratories Ltd - ADR and enter the required number of quantities and click on buy to purchase the shares of Dr Reddy's Laboratories Ltd - ADR.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Address: 8-2-337, Road No. 3, Hyderabad, India, 500034
The CEO & director of Mr. Gunupati Venkateswara Prasad B.E.. is Dr Reddy's Laboratories Ltd - ADR, and CFO & Sr. VP is Mr. Kallam Satish Reddy B.Tech., M.S..
There is no promoter pledging in Dr Reddy's Laboratories Ltd - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Dr. Reddy's Laboratories Ltd - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
17.28
|
|
Operating margin(%)
|
23.2
|
|
Net Margin(%)
|
17.24
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Dr Reddy's Laboratories Ltd - ADR was $0 Mln.
$0.20
(
